Dong-A ST Co., Ltd. (170900.KS)
KRW 44850.0
(0.0%)
KRW 44850.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 406.7 Billion KRW | 30.28% |
| 2022 | 312.18 Billion KRW | 3.86% |
| 2021 | 300.57 Billion KRW | 45.28% |
| 2020 | 206.89 Billion KRW | 0.03% |
| 2019 | 206.84 Billion KRW | -1.59% |
| 2018 | 210.18 Billion KRW | 16.55% |
| 2017 | 180.34 Billion KRW | -38.38% |
| 2016 | 292.65 Billion KRW | -21.45% |
| 2015 | 372.57 Billion KRW | -16.97% |
| 2014 | 448.72 Billion KRW | 26.36% |
| 2013 | 355.12 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 592.39 Billion KRW | 22.51% |
| 2024 Q1 | 483.56 Billion KRW | 18.9% |
| 2023 Q4 | 406.7 Billion KRW | 0.56% |
| 2023 Q1 | 342.7 Billion KRW | 9.78% |
| 2023 FY | 406.7 Billion KRW | 30.28% |
| 2023 Q3 | 404.45 Billion KRW | 1.12% |
| 2023 Q2 | 399.97 Billion KRW | 16.71% |
| 2022 FY | 312.18 Billion KRW | 3.86% |
| 2022 Q1 | 359.41 Billion KRW | 19.58% |
| 2022 Q2 | 361.89 Billion KRW | 0.69% |
| 2022 Q4 | 312.18 Billion KRW | -14.72% |
| 2022 Q3 | 366.06 Billion KRW | 1.15% |
| 2021 Q4 | 300.57 Billion KRW | 0.2% |
| 2021 Q2 | 206.33 Billion KRW | -0.24% |
| 2021 FY | 300.57 Billion KRW | 45.28% |
| 2021 Q1 | 206.83 Billion KRW | -0.03% |
| 2021 Q3 | 299.98 Billion KRW | 45.39% |
| 2020 Q1 | 207.39 Billion KRW | 0.27% |
| 2020 FY | 206.89 Billion KRW | 0.03% |
| 2020 Q4 | 206.89 Billion KRW | -0.98% |
| 2020 Q3 | 208.93 Billion KRW | 0.6% |
| 2020 Q2 | 207.69 Billion KRW | 0.14% |
| 2019 Q3 | 256.46 Billion KRW | 0.33% |
| 2019 Q4 | 206.84 Billion KRW | -19.35% |
| 2019 Q1 | 213.99 Billion KRW | 1.81% |
| 2019 FY | 206.84 Billion KRW | -1.59% |
| 2019 Q2 | 255.63 Billion KRW | 19.46% |
| 2018 FY | 210.18 Billion KRW | 16.55% |
| 2018 Q4 | 210.18 Billion KRW | -0.36% |
| 2018 Q3 | 210.94 Billion KRW | 0.01% |
| 2018 Q2 | 210.93 Billion KRW | -12.28% |
| 2018 Q1 | 240.47 Billion KRW | 33.34% |
| 2017 Q1 | 293.54 Billion KRW | 0.3% |
| 2017 Q2 | 269.7 Billion KRW | -8.12% |
| 2017 Q3 | 189.91 Billion KRW | -29.58% |
| 2017 Q4 | 180.34 Billion KRW | -5.04% |
| 2017 FY | 180.34 Billion KRW | -38.38% |
| 2016 Q2 | 342.33 Billion KRW | -0.48% |
| 2016 FY | 292.65 Billion KRW | -21.45% |
| 2016 Q4 | 292.65 Billion KRW | -9.81% |
| 2016 Q3 | 324.49 Billion KRW | -5.21% |
| 2016 Q1 | 343.99 Billion KRW | -7.67% |
| 2015 Q4 | 372.57 Billion KRW | -0.12% |
| 2015 FY | 372.57 Billion KRW | -16.97% |
| 2015 Q3 | 373.03 Billion KRW | -14.7% |
| 2015 Q2 | 437.34 Billion KRW | -2.48% |
| 2015 Q1 | 448.48 Billion KRW | -0.05% |
| 2014 FY | 448.72 Billion KRW | 26.36% |
| 2014 Q1 | 336.87 Billion KRW | -5.14% |
| 2014 Q2 | 376.43 Billion KRW | 11.74% |
| 2014 Q3 | 377.8 Billion KRW | 0.37% |
| 2014 Q4 | 448.72 Billion KRW | 18.77% |
| 2013 Q2 | 333.84 Billion KRW | 0.0% |
| 2013 Q3 | 335.82 Billion KRW | 0.59% |
| 2013 Q4 | 355.12 Billion KRW | 5.75% |
| 2013 FY | 355.12 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -742.819% |
| Yuhan Corporation | 230.07 Billion KRW | -76.773% |
| Yuhan Corporation | 230.07 Billion KRW | -76.773% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -932.059% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -932.059% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -932.059% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | -6.451% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -131.241% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 41.218% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -138.844% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -138.844% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -138.844% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -68198.059% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 13.103% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -839.863% |
| HANDOK Inc. | 300.01 Billion KRW | -35.564% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -135.048% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -1226.411% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -412.308% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -124.702% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -170694.121% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -178.47% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -508.093% |
| Boryung Corporation | 204.21 Billion KRW | -99.155% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -937.383% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -242.811% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -377.579% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -377.579% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 13.071% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | -72.595% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -31414.595% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -64249.491% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -349.486% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -781.241% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -781.241% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -908.218% |
| CKD Bio Corp. | 146.92 Billion KRW | -176.808% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 13.409% |
| JW Holdings Corporation | 554.58 Billion KRW | 26.665% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | -80.715% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 29.005% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | -85.065% |
| JW Lifescience Corporation | 46.31 Billion KRW | -778.17% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | -86.698% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -378.67% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -1432.824% |